A Novel Spectrophotometric Approach for Estimation of Non-steroidal anti-inflammatory drugs (NSAIDs) in Pharmaceutical Drug formulations by Neocuproine

A novel, simple, accurate, sensitive, reproducible, economical method for spectrophotometric approach for measuring MFA in Pharmaceutical Drug formulations was successfully developed and verified. A novel analytical technique for estimating MFA 250 mg in capsule pharmaceutical formulations for different brands was established. The method suggested is based on the reduction of Cu(II)-2,9DMP complex to colored Cu(I)- 2,9DMP complex. The optimum experimental conditions have been achieved. Beer'ss Law holds true in the concentration levels 5.0-60 μg/mL with accurate molar absorptivity of 0.238 L/mol.cm at 454 nm and “detection limit” was 0.5882 μg/mL and the limit of quantification was 1.7825 μg/mL and correlation coefficient obtained has been near to one. The Effect of pH, reaction time, Buffer Solutions, Volume of Cu(ІІ), Volume of 2,9.DMP reagent, temperature, Order of Addition, and Effect of Acid on the determination of MFA, have been examined. The proposed method has been successfully utilized for quantitative assessment of commercially produced dosage modes. Our research sought to develop a fresh, accurate, and sensitive technique for measuring MFA as a pure pharmacological product and as a hard dosage. The creation of a metal complex of MFA with a copper ion is a prerequisite for the spectrophotometric approach.